Intersect Ent 주식 주식분석 | 주식가격 | 뉴스 | XENT | US46071F1030 | A117WV

날짜	Intersect Ent 주식 가격
	28.24 undefined
	28.24 undefined

날짜	Intersect Ent 매출	Intersect Ent EBIT	Intersect Ent 이익
2025e	208.44 백만 undefined	0 undefined	-52.47 백만 undefined
2024e	194.1 백만 undefined	-43.83 백만 undefined	-43.81 백만 undefined
2023e	172.49 백만 undefined	-41.89 백만 undefined	-37.31 백만 undefined
2022e	137.82 백만 undefined	-40.84 백만 undefined	-38.28 백만 undefined
2021	106.75 백만 undefined	-72.68 백만 undefined	-159.63 백만 undefined
2020	80.6 백만 undefined	-67.7 백만 undefined	-72.3 백만 undefined
2019	109.1 백만 undefined	-45.4 백만 undefined	-43 백만 undefined
2018	108.5 백만 undefined	-25 백만 undefined	-22.9 백만 undefined
2017	96.3 백만 undefined	-17.6 백만 undefined	-16.4 백만 undefined
2016	78.7 백만 undefined	-26.1 백만 undefined	-25.2 백만 undefined
2015	61.6 백만 undefined	-26.9 백만 undefined	-26.6 백만 undefined
2014	38.6 백만 undefined	-18.1 백만 undefined	-18.4 백만 undefined
2013	17.9 백만 undefined	-18 백만 undefined	-18.4 백만 undefined
2012	5.9 백만 undefined	-16.5 백만 undefined	-16.4 백만 undefined

	매출	EBIT	이익
2012	5.9 백만 USD	-16.5 백만 USD	-16.4 백만 USD
2013	17.9 백만 USD	-18 백만 USD	-18.4 백만 USD
2014	38.6 백만 USD	-18.1 백만 USD	-18.4 백만 USD
2015	61.6 백만 USD	-26.9 백만 USD	-26.6 백만 USD
2016	78.7 백만 USD	-26.1 백만 USD	-25.2 백만 USD
2017	96.3 백만 USD	-17.6 백만 USD	-16.4 백만 USD
2018	108.5 백만 USD	-25 백만 USD	-22.9 백만 USD
2019	109.1 백만 USD	-45.4 백만 USD	-43 백만 USD
2020	80.6 백만 USD	-67.7 백만 USD	-72.3 백만 USD
2021	106.75 백만 USD	-72.68 백만 USD	-159.63 백만 USD
2022e	137.82 백만 USD	-40.84 백만 USD	-38.28 백만 USD
2023e	172.49 백만 USD	-41.89 백만 USD	-37.31 백만 USD
2024e	194.1 백만 USD	-43.83 백만 USD	-43.81 백만 USD
2025e	208.44 백만 USD	0 USD	-52.47 백만 USD

2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022e	2023e	2024e	2025e
5	17	38	61	78	96	108	109	80	106	137	172	194	208
-	240.00	123.53	60.53	27.87	23.08	12.50	0.93	-26.61	32.50	29.25	25.55	12.79	7.22
40.00	52.94	73.68	80.33	83.33	83.33	78.70	79.82	62.50	71.70	-	-	-	-
2	9	28	49	65	80	85	87	50	76	0	0	0	0
-16	-18	-18	-26	-26	-17	-25	-45	-67	-72	-40	-41	-43	0
-320.00	-105.88	-47.37	-42.62	-33.33	-17.71	-23.15	-41.28	-83.75	-67.92	-29.20	-23.84	-22.16	-
-16	-18	-18	-26	-25	-16	-22	-43	-72	-159	-38	-37	-43	-52
-	12.50	-	44.44	-3.85	-36.00	37.50	95.45	67.44	120.83	-76.10	-2.63	16.22	20.93
22.5	22.5	11.4	26.2	28.4	29.1	30.3	31.4	32.6	33.27	0	0	0	0
-	-	-	-	-	-	-	-	-	-	-	-	-	-

2012	2013	2014	2015	2016	2017	2018	2019	2020	2021

2.1	12.3	48.4	124.3	103.9	102.3	100.8	90.6	88	61.02
1.3	4.2	8.3	11.5	14.4	16.6	19.6	19.1	14.6	17.33
100	100	0	0	0	0	0	0	0	0
1.4	2.2	2.5	3.9	5.6	8.5	11.6	17	12.1	18.6
0.4	0.4	0.9	1.5	1.3	2.9	2.7	2.3	3.5	9.05
5.3	19.2	60.1	141.2	125.2	130.3	134.7	129	118.2	106
1.8	1.7	1.5	3.2	4.1	4.8	5.9	18.3	22.8	20.14
0	0	0	0	0	0	0	0	0	0
100	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	21.2	0
0	0	0	0	0	0	0	0	46.6	0
0.1	0.1	1.2	0.2	0.4	0.4	0.4	0.6	18.6	20.73
2	1.8	2.7	3.4	4.5	5.2	6.3	18.9	109.2	40.87
7.3	21	62.8	144.6	129.7	135.5	141	147.9	227.4	146.87

60.3	90.8	0	0	0	0	0	0	0	0.03
1.2	1.9	150.4	253.5	262.9	282.1	308.8	348.7	370.1	393.62
-59.9	-78.3	-96.6	-123.3	-148.5	-164.8	-187.8	-230.8	-303.1	-462.71
0	-200	0	0	0	-100	0	100	0	-10
0	0	0	0	0	0	0	0	0	0
1.6	14.2	53.8	130.2	114.4	117.2	121	118	67	-69.07
1.1	1.5	2.1	1.9	3.3	3.4	6.2	4.1	6	8.89
1.9	3	5.1	9.6	10.2	13.2	12.3	14.1	14.3	22.48
0.5	1	0.9	1.6	0.9	1.1	1.3	0.8	23.9	25.8
0	0	0	0	0	0	0	0	0	0
600	700	0	0	0	0	0	0	0	0
4.1	6.2	8.1	13.1	14.4	17.7	19.8	19	44.2	57.17
1.4	0.8	0	0	0	0	0	0	63.7	127.35
0	0	0	0	0	0	0	0	1.6	0
0.2	0.1	1	1.3	1	0.7	0.2	10.9	50.9	31.43
1.6	0.9	1	1.3	1	0.7	0.2	10.9	116.2	158.78
5.7	7.1	9.1	14.4	15.4	18.4	20	29.9	160.4	215.95
7.3	21.3	62.9	144.6	129.8	135.6	141	147.9	227.4	146.88

2012	2013	2014	2015	2016	2017	2018	2019	2020	2021
-16	-18	-18	-26	-25	-16	-22	-42	-72	-159
0	0	0	0	1	1	1	3	5	4
0	0	0	0	0	0	0	0	0	-1
0	-2	-2	0	-3	-2	-5	-7	12	-7
0	0	1	5	7	9	12	18	19	104
0	0	0	0	0	0	0	0	1	3
0	0	0	0	0	0	0	0	0	0
-16	-19	-17	-20	-20	-8	-13	-27	-35	-59
-1	0	0	-1	-2	-2	-2	-3	0	-2
5	0	-35	-56	-6	9	-10	18	-22	49
7	0	-35	-55	-4	11	-7	22	-21	51
0	0	0	0	0	0	0	0	0	0
2	0	-1	0	0	0	0	0	61	49
0	30	56	98	1	8	13	19	6	7
2	29	54	98	1	8	13	19	68	36
-	-	-	-	-	-	-	-	-	-20.00
0	0	0	0	0	0	0	0	0	0
-7	10	1	21	-24	9	-10	11	10	25
0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0

Intersect Ent 브루토마진	Intersect Ent 이익 마진	Intersect Ent EBIT-마진	Intersect Ent 이익 마진
2025e	71.89 %	0 %	-25.17 %
2024e	71.89 %	-22.58 %	-22.57 %
2023e	71.89 %	-24.29 %	-21.63 %
2022e	71.89 %	-29.64 %	-27.78 %
2021	71.89 %	-68.08 %	-149.54 %
2020	62.28 %	-84 %	-89.7 %
2019	80.11 %	-41.61 %	-39.41 %
2018	79.17 %	-23.04 %	-21.11 %
2017	83.9 %	-18.28 %	-17.03 %
2016	83.48 %	-33.16 %	-32.02 %
2015	80.03 %	-43.67 %	-43.18 %
2014	73.58 %	-46.89 %	-47.67 %
2013	54.75 %	-100.56 %	-102.79 %
2012	33.9 %	-279.66 %	-277.97 %

	브루토마진	EBIT-마진	이익 마진
2012	33.9 %	-279.66 %	-277.97 %
2013	54.75 %	-100.56 %	-102.79 %
2014	73.58 %	-46.89 %	-47.67 %
2015	80.03 %	-43.67 %	-43.18 %
2016	83.48 %	-33.16 %	-32.02 %
2017	83.9 %	-18.28 %	-17.03 %
2018	79.17 %	-23.04 %	-21.11 %
2019	80.11 %	-41.61 %	-39.41 %
2020	62.28 %	-84 %	-89.7 %
2021	71.89 %	-68.08 %	-149.54 %
2022e	71.89 %	-29.64 %	-27.78 %
2023e	71.89 %	-24.29 %	-21.63 %
2024e	71.89 %	-22.58 %	-22.57 %
2025e	71.89 %	0 %	-25.17 %

날짜	Intersect Ent 주당 매출	Intersect Ent EBIT 당 주식	Intersect Ent 주당 이익
2025e	6.17 undefined	0 undefined	-1.55 undefined
2024e	5.74 undefined	0 undefined	-1.3 undefined
2023e	5.1 undefined	0 undefined	-1.1 undefined
2022e	4.08 undefined	0 undefined	-1.13 undefined
2021	3.21 undefined	-2.18 undefined	-4.8 undefined
2020	2.47 undefined	-2.08 undefined	-2.22 undefined
2019	3.47 undefined	-1.45 undefined	-1.37 undefined
2018	3.58 undefined	-0.83 undefined	-0.76 undefined
2017	3.31 undefined	-0.6 undefined	-0.56 undefined
2016	2.77 undefined	-0.92 undefined	-0.89 undefined
2015	2.35 undefined	-1.03 undefined	-1.02 undefined
2014	3.39 undefined	-1.59 undefined	-1.61 undefined
2013	0.8 undefined	-0.8 undefined	-0.82 undefined
2012	0.26 undefined	-0.73 undefined	-0.73 undefined

	주당 매출	EBIT 당 주식	주당 이익
2012	0.26 USD	-0.73 USD	-0.73 USD
2013	0.8 USD	-0.8 USD	-0.82 USD
2014	3.39 USD	-1.59 USD	-1.61 USD
2015	2.35 USD	-1.03 USD	-1.02 USD
2016	2.77 USD	-0.92 USD	-0.89 USD
2017	3.31 USD	-0.6 USD	-0.56 USD
2018	3.58 USD	-0.83 USD	-0.76 USD
2019	3.47 USD	-1.45 USD	-1.37 USD
2020	2.47 USD	-2.08 USD	-2.22 USD
2021	3.21 USD	-2.18 USD	-4.8 USD
2022e	4.08 USD	0 USD	-1.13 USD
2023e	5.1 USD	0 USD	-1.1 USD
2024e	5.74 USD	0 USD	-1.3 USD
2025e	6.17 USD	0 USD	-1.55 USD

	주식 수량
2012	22.5 백만 Aktien
2013	22.5 백만 Aktien
2014	11.4 백만 Aktien
2015	26.2 백만 Aktien
2016	28.4 백만 Aktien
2017	29.1 백만 Aktien
2018	30.3 백만 Aktien
2019	31.4 백만 Aktien
2020	32.6 백만 Aktien
2021	33.27 백만 Aktien
2022e	33.27 백만 Aktien
2023e	33.27 백만 Aktien
2024e	33.27 백만 Aktien
2025e	33.27 백만 Aktien

%-지분	이름	주식	변경
9.89993 %	Versor Investments LP	3,347,165	172,068
7.59850 %	Magnetar Capital Partners LP	2,569,052	11,289
6.79788 %	BlackRock Institutional Trust Company, N.A.	2,298,364	46,295
5.32862 %	The Vanguard Group, Inc.	1,801,606	19,717
5.02169 %	First Light Asset Management, LLC	1,697,834	-438,989
4.18397 %	Alpine Associates Management Inc.	1,414,600	21,600
2.97728 %	Millennium Management LLC	1,006,619	-623,549
2.80884 %	State Street Global Advisors (US)	949,670	-70,062
2.78024 %	Rock Springs Capital Management LP	940,000	-280,000
2.27610 %	Morgan Stanley & Co. LLC	769,548	82,382
1.85115 %	Westchester Capital Management, LLC	625,873	428,163
1.81899 %	Melqart Asset Management (UK) Limited	615,000	615,000
1.77107 %	Goldman Sachs & Company, Inc.	598,800	187,073
1.70657 %	Nuance Investments, LLC	576,992	108,438
1.68091 %	Geode Capital Management, L.L.C.	568,314	1,888
1.64077 %	Candriam S.A. (France)	554,744	0
1.53410 %	AllianceBernstein L.P.	518,678	11,240
1.52582 %	BofA Global Research (US)	515,880	251,593
1.34988 %	Omni Partners US LLC	456,396	456,396
1.30683 %	Omni Event Management Ltd	441,838	441,838
1.27550 %	Gabelli Funds, LLC	431,245	83,529
1.15712 %	AQR Capital Management, LLC	391,222	0
1.08489 %	Alberta Investment Management Corporation	366,800	102,124
1.08311 %	Ostrum Asset Management	366,200	366,200
1.05993 %	Nuveen LLC	358,364	-11,078
0.93017 %	Northern Trust Investments, Inc.	314,492	-6,756
0.92686 %	Ergoteles Capital	313,371	59,170
0.80870 %	Crabel Capital Management, L.L.C.	273,423	0
0.79442 %	Cowen Investment Management LLC	268,592	172,623
0.76501 %	Moll (Frederic H)	258,649	12,500
0.71872 %	Norges Bank Investment Management (NBIM)	243,000	186,300
0.71565 %	State of Wisconsin Investment Board	241,960	35,000
0.71133 %	Aberdeen Asset Managers Ltd.	240,500	240,500
0.70520 %	Charles Schwab Investment Management, Inc.	238,428	10,099
0.68840 %	J.P. Morgan Securities LLC	232,747	225,436
0.65237 %	EHP Funds Inc.	220,567	220,567
0.59860 %	Calamos Advisors LLC	202,386	202,386
0.59078 %	Candriam Belgium S.A.	199,744	199,744
0.46566 %	BlackRock Financial Management, Inc.	157,439	2,342
0.43212 %	Premier Asset Management, LLC	146,100	0
0.42862 %	Glazer Capital, LLC	144,918	144,918
0.36971 %	Ohio Public Employees Retirement System	125,000	35,000
0.35607 %	Qube Research & Technologies Ltd	120,388	68,856
0.32268 %	Havens Advisors, L.L.C.	109,097	-52,103
0.31734 %	DWS Investments UK Limited	107,292	88,144
0.31417 %	Citi Investment Research (US)	106,221	-241,922
0.30730 %	Ersel Asset Management SGR S.p.A.	103,898	56,986
0.30661 %	RBC Capital Partners	103,665	25,804
0.30169 %	CPP Investment Board	102,000	-60,200
0.29584 %	BlackRock Investment Management, LLC	100,023	-1,964
0.28620 %	D. E. Shaw & Co., L.P.	96,764	-73,740
0.28196 %	Capstone Investment Advisors, LLC	95,329	-31,092
0.26898 %	Keebeck Alpha, LP	90,942	0
0.26718 %	IndexIQ Advisors LLC	90,332	-4,375
0.25683 %	Deutsche Asset Management Americas	86,835	-1
0.24394 %	West (Thomas A)	82,475	-93,954
0.23601 %	LMR Partners LLP	79,794	0
0.23423 %	Barclays Bank PLC	79,194	-34,320
0.22480 %	BNY Mellon Asset Management	76,006	-1,727
0.22351 %	Weiss Multi-Strategy Advisers LLC	75,569	-832
0.22025 %	Credit Suisse Asset Management	74,466	31,231
0.20586 %	Schweizerische Nationalbank	69,600	0
0.19856 %	Yakira Capital Management, Inc.	67,132	67,132
0.19390 %	Marshall Wace LLP	65,558	65,558
0.19174 %	Cigogne Management S.A.	64,828	64,828
0.18476 %	Credit Suisse Asset Management, LLC (US)	62,468	35,162
0.15813 %	Invesco Canada Ltd.	53,463	7,306
0.14562 %	BlackRock Investment Management (UK) Ltd.	49,234	-68
0.14401 %	Susquehanna International Group, LLP	48,691	14,477
0.14170 %	Dimensional Fund Advisors, L.P.	47,910	0
0.13232 %	California State Teachers Retirement System	44,738	601
0.11830 %	Raymond James & Associates, Inc.	39,996	4,045
0.11433 %	Guggenheim Investments	38,656	471
0.11110 %	Northern Trust Global Investments	37,563	-3,246
0.10983 %	Meier (Richard A)	37,132	-16,996
0.10585 %	Prelude Capital Management, LLC	35,789	8,362
0.10348 %	HAP Trading, LLC	34,988	20,000
0.10215 %	JP Morgan Asset Management	34,538	-228,134
0.10137 %	Gallahue (Kieran T.)	34,273	0
0.09815 %	Credit Suisse International	33,184	-249
0.09614 %	Mellon Investments Corporation	32,504	2,800
0.09613 %	State Teachers Retirement System of Ohio	32,500	0
0.09609 %	Russell Investments Trust Company	32,487	-12,485
0.09403 %	Rhumbline Advisers Ltd. Partnership	31,792	-6,112
0.09340 %	ClearBridge Investments, LLC	31,579	7,041
0.09245 %	UBS Financial Services, Inc.	31,259	17,936
0.08873 %	Banca del Sempione SA	30,000	30,000
0.08873 %	Allianz Global Investors GmbH	30,000	0
0.08728 %	Putnam Investment Management, L.L.C.	29,508	1,517
0.08655 %	Hightower Advisors, LLC	29,262	0
0.08108 %	Verition Fund Management LLC	27,412	14,061
0.07780 %	State Street Global Advisors (UK) Ltd.	26,305	-21
0.07759 %	BlackRock Advisors (UK) Limited	26,233	305
0.07741 %	State Street Global Advisors Ireland Limited	26,171	142
0.07728 %	Citadel Advisors LLC	26,127	-87,157
0.07647 %	ArrowMark Colorado Holdings, LLC	25,855	0
0.07394 %	S. Muoio & Co. LLC	25,000	0
0.07394 %	Pentwater Capital Management LP	25,000	25,000
0.07366 %	Carscadden (Gwen R)	24,903	-1,416
0.07091 %	New York State Common Retirement Fund	23,975	-77

What values and corporate philosophy does Intersect Ent represent?

Intersect Ent Inc represents a strong commitment to advancing patient care in the field of ear, nose, and throat (ENT) disorders. The company focuses on developing innovative treatments that improve the quality of life for individuals suffering from chronic sinusitis. Intersect Ent Inc integrates cutting-edge technologies and research to provide minimally invasive and clinically proven solutions. With a patient-centric approach, the company strives to enhance patient outcomes and experiences. By maintaining a culture of excellence, collaboration, and integrity, Intersect Ent Inc continually seeks to revolutionize the ENT industry and set new standards for medical innovation.

In which countries and regions is Intersect Ent primarily present?

Intersect Ent Inc is primarily present in the United States.

What significant milestones has the company Intersect Ent achieved?

Intersect Ent Inc has achieved several significant milestones. Notably, the company developed and commercialized Propel and Propel Mini, innovative steroid-releasing sinus implants, which revolutionized the treatment of chronic sinusitis. Intersect Ent Inc also gained FDA approval for Propel Contour, a next-generation sinus implant with improved delivery capability. Additionally, the company has successfully expanded its product portfolio and worldwide reach, securing partnerships and distribution agreements with leading global healthcare companies. Through continuous innovation and dedication, Intersect Ent Inc continues to improve the lives of patients suffering from chronic sinusitis while solidifying its position as a market leader in the field.

What is the history and background of the company Intersect Ent?

Intersect Ent Inc. is a renowned medical technology company specializing in the development of innovative therapies for chronic sinusitis patients. Founded in 2003, Intersect Ent has become a leader in improving the quality of life for people suffering from sinus-related illnesses. The company's groundbreaking approach involves the use of localized drug delivery systems to provide effective and long-lasting relief to patients. Intersect Ent has consistently pushed the boundaries of medical advancements and has earned recognition for its revolutionary technology. With a strong commitment to patient care, the company continues to strive for excellence in addressing the needs of those affected by chronic sinusitis.

Who are the main competitors of Intersect Ent in the market?

The main competitors of Intersect Ent Inc in the market are Medtronic, Johnson & Johnson, and Olympus Corporation.

In which industries is Intersect Ent primarily active?

Intersect Ent Inc is primarily active in the healthcare industry, specifically in the field of medical devices. They specialize in the development and manufacturing of innovative therapies for ear, nose, and throat conditions. With a strong focus on providing minimally invasive solutions, Intersect Ent Inc aims to enhance patients' quality of life and improve treatment outcomes. The company's dedication to advancing medical innovations has established them as a trusted player in the healthcare sector.

What is the business model of Intersect Ent?

Intersect Ent Inc. operates under a business model focused on developing and commercializing innovative therapies for patients with ear, nose, and throat (ENT) conditions. The company specializes in designing and delivering localized therapies directly to the site of a patient's disease. This enables precise, effective treatment while reducing the need for invasive surgeries. Intersect Ent Inc. aims to provide long-term solutions for patients suffering from chronic sinusitis and related conditions. Their business model revolves around leveraging advanced technology and medical expertise to improve the quality of life for individuals affected by ENT disorders.

Intersect Ent 2024의 P/E 비율은 얼마입니까?

Intersect Ent의 P/E 비율은 -21.44입니다.

Intersect Ent 2024의 KUV는 얼마입니까?

Intersect Ent의 P/S 비율은 4.84입니다.

Intersect Ent의 AlleAktien 품질 점수는 얼마인가요?

Intersect Ent에 대한 AlleAktien 품질 점수는 4/10입니다.

Intersect Ent 2024의 매출은 얼마인가요?

예상되는 Intersect Ent 매출은 194.1 백만 USD입니다.

Intersect Ent 2024의 이익은 얼마인가요?

예상되는 Intersect Ent 이익은 -43.81 백만 USD입니다.

Intersect Ent은 무엇을 하나요?

Intersect Ent Inc is an American company that manufactures and distributes medical devices for the treatment of ear, nose, and throat problems. The company was founded in 2003 and is headquartered in Menlo Park, California. It specializes in two main areas: the ear and the otolaryngology (ENT) field. In the ear area, Intersect Ent Inc offers innovative products to treat patients with chronic sinusitis and rhinosinus polyposis. In the ENT field, the company offers a wide range of products to treat conditions such as sinusitis, allergic rhinitis, and nasal congestion. The company is known for its innovative technologies that improve methods for treating ear, nose, and throat problems. It operates in North America, Europe, and Asia and collaborates with partner companies and distributors to expand its market share. The company also strives to collaborate with medical professionals, research institutions, and industry organizations to improve and develop its products and services. Overall, Intersect Ent Inc is a growing player in the ENT medicine market and is committed to improving the quality of life of patients by offering innovative solutions that simplify the treatment of ear, nose, and throat problems.